FDA approves dupilumab for chronic rhinosinusitis with nasal polyps
Reuters (6/26, Mathias, Mishra) reports that on June 26, the Food and Drug Administration “approved Regeneron Pharmaceuticals Inc and Sanofi SA’s drug Dupixent [dupilumab] to treat nasal polyps.” The injectable drug “is for use with other medicines to treat patients suffering from chronic rhinosinusitis with nasal polyps, the companies said in a joint statement.” The FDA first approved the drug two years ago “for moderate-to-severe atopic dermatitis, or eczema, and in 2018 it won U.S. approval to treat moderate-to-severe asthma as well.” AMA Morning Rounds 6/27/2019